We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+0.36%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$782M
AUM Growth
+$134M
Cap. Flow
-$119M
Cap. Flow %
-15.2%
Top 10 Hldgs %
66.62%
Holding
166
New
28
Increased
41
Reduced
46
Closed
40

Top Buys

Rank Stock Value
1
ORMP icon
Oramed Pharmaceuticals
ORMP
+$4.16M
2
NKTR icon
Nektar Therapeutics
NKTR
+$3.04M
3
VKTX icon
Viking Therapeutics
VKTX
+$1.95M
4
FOLD
Amicus Therapeutics
FOLD
+$1.63M
5
GNPX icon
Genprex
GNPX
+$1.42M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$40.1M
2
NVO
Novo Nordisk
NVO
+$19.8M
3
SSKN
Strata Skin Sciences
SSKN
+$3.45M
4
INCY icon
Incyte
INCY
+$2.77M
5
AZN icon
AstraZeneca
AZN
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 15.01%
2 Consumer Staples 0.29%
3 Financials 0.12%
4 Technology 0.09%
5 Materials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPHS
76
PUT
DELISTED
Sophiris Bio, Inc.
SPHS
$440K 0.06%
1,578
+59
+4% +$168
BPTH
77
DELISTED
Bio-Path Holdings Inc
BPTH
$437K 0.06%
+2,427
New +$1.31M
QNRX
78
Quoin Pharmaceuticals
QNRX
$8.44M
$412K 0.05%
1
– –
MBOT icon
79
Microbot Medical
MBOT
$113M
$405K 0.05%
54,518
+21,539
+65% +$186K
CARM
80
PUT
DELISTED
Carisma Therapeutics
CARM
$392K 0.05%
91
+41
+82% +$1.6K
BIOC
81
DELISTED
Biocept, Inc.
BIOC
$392K 0.05%
475
+455
+2,275% +$580K
FCEL icon
82
PUT
FuelCell Energy
FCEL
$1.57B
$372K 0.05%
10
-5
-33% -$2.16K
MBAI
83
Check-Cap
MBAI
$8.12M
$363K 0.05%
4,539
+1,282
+39% +$94.1K
SIOX
84
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$327K 0.04%
16,909
-1,404
-8% -$25.5K
MDGL icon
85
Madrigal Pharmaceuticals
MDGL
$12.4B
$321K 0.04%
+1,500
New +$376K
TTNP
86
DELISTED
Titan Pharmaceuticals
TTNP
$314K 0.04%
+422
New +$1.15M
INSM icon
87
Insmed
INSM
$22.6B
$303K 0.04%
15,000
-2,800
-16% -$63.2K
ISEE
88
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$287K 0.04%
1,217
– –
AIM
89
AIM ImmunoTech
AIM
$6.54M
$263K 0.03%
260
-181
-41% -$221K
DBVT
90
CALL
DBV Technologies
DBVT
$799M
$261K 0.03%
12
-16
-57% -$3.25K
HSTO
91
CALL
DELISTED
Histogen Inc. Common Stock
HSTO
$253K 0.03%
+2
New +$1.84K
NSPR icon
92
InspireMD
NSPR
$32.1M
$236K 0.03%
1,428
+597
+72% +$94.7K
CHEKZ
93
DELISTED
Check-Cap Ltd. Series C Warrant
CHEKZ
$230K 0.03%
306,878
-321,968
-51% -$205K
VIRX
94
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$191K 0.02%
27
-39
-59% -$2.96K
TPST icon
95
Tempest Therapeutics
TPST
$13.9M
$187K 0.02%
87
-239
-73% -$574K
AIXC
96
AIxCrypto Holdings Inc
AIXC
$16.7M
$186K 0.02%
+8
New +$207K
DRRX
97
DELISTED
DURECT Corp
DRRX
$145K 0.02%
13,190
+2,422
+22% +$32.9K
APDNW
98
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$136K 0.02%
616,043
-47,835
-7% -$10.9K
CRDF icon
99
Cardiff Oncology
CRDF
$63.6M
$125K 0.02%
25,606
-99,486
-80% -$471K
ADVM
100
PUT
DELISTED
Adverum Biotechnologies
ADVM
$102K 0.01%
+17
New +$955
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sabby Management held 166 positions worth $782M, up 21% from $647M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $119M in Q3 2018, closing 40 positions and reducing 46 holdings. Its most notable exit was Novo Nordisk, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 26% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Sabby Management opened a new position in Oramed Pharmaceuticals worth $3.88M.

  • Sabby Management's largest Q3 2018 buy was Oramed Pharmaceuticals: 801,242 shares worth $3.88M.
  • Sabby Management added most to Nektar Therapeutics in Q3 2018, an estimated $3.04M increase.
  • Sabby Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $40.1M.
  • Sabby Management fully exited Novo Nordisk in Q3 2018, selling an estimated $19.8M.
  • Sabby Management's ten largest holdings make up 67% of its $782M portfolio in Q3 2018.
  • Sabby Management opened 28 new positions and closed 40 in Q3 2018.
  • Sabby Management's portfolio value rose 21% quarter-over-quarter to $782M.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.